While mutations in ras are found in a high percentage of human tumours, additional mutations are required for progression from transformation to full-blown oncogenesis. Identifying such cooperating mutations is key for understanding the progression in humans. In C. elegans, worms homozygous for activating mutations in the ras orthologue
let-60 have multivulva phenotypes (Muv), with approximately 60 percent of
let-60(
n1046) animals being multivulval at 20 deg C. Therefore, we use this phenotype as the basis for a large-scale RNAi screen to identify either enhancers or suppressors of the
let-60(
n1046) Muv phenotype. Since ras and many cooperating signaling pathways are well conserved between worms and humans, RNAi knockdowns that decrease the percentage of Muv worms are likely to uncover orthologs of protooncogenes, whereas knockdowns that increase the percentage of Muv worms should uncover tumor suppressor gene orthologs. Therefore, we use RNAi screening in C. elegans to identify novel cancer associated genes in humans. Rather than carry out genome-scale screens, we focused on two sets of genes to test initially. The first is a set of ~250 chromatin remodeling factors. Many chromatin remodeling factors have been implicated roles in cancer including
p105Rb, histone acetyl transferases, and NuRD complex components. In worms, the SynMuv genes repress the vulval fate and they encode nuclear proteins that function principally through chromatin remodeling. Thus chromatin remodeling factors are likely to be enriched in regulators of Ras signaling in both vulval induction and carcinogenesis. We present here our data from screening all 250 chromatin remodeling factors for enhancers or suppressors of the
let-60(
n1046) Muv phenotype. The second set of genes was chosen as orthologues of human genes whose mutation in cancers is being studied in depth by The Cancer Genome Atlas Project. This is a collaborative effort to sequence tumor genomes from tumor samples. In the pilot projects, 623 known cancer-associated genes were selected for gene sequencing and we are screening all orthologues of these genes in the worm for enhancers or suppressors of the
let-60(
n1046) Muv phenotype. Since the cancer genomes may accumulate higher background mutation rates, the presence or the frequency of mutations uncovered by DNA sequencing may not indicate the biological relevance of the mutations themselves. We hope that the studies we are carrying out in the worm will aid assigning biological relevance to the identified mutations in tumours. We will present the results from these screens here.